Chinese Medicine Treat for Hypertensive Renal Injury

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 520 participants.

Also called NCT04078711

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 520 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04078711
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04078711. Randomized; double masking; primary purpose treatment. Start 2019-09-10 (anticipated); primary completion 2021-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Chinese Medicine Treat for Hypertensive Renal Injury
Acronym
CHAIR
Condition
Hypertension
Condition
Renal Injury
Intervention (Drug)
Losartan 100Mg Tab
Intervention (Drug)
Qianyangyuyin 20g Granule
Intervention (Drug)
placebo
Lead sponsor
Jiangsu Province Hospital of Traditional Chinese Medicine (class: other)
Collaborator
Ministry of Science and Technology of the People´s Republic of China (class: other government)
Collaborator
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (class: other)
Collaborator
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine (class: other)

Record details

Record id
cardio:ct-nct04078711
Content hash
52b39f472c9f098d7b0e3e9132c41b4012c2d0b1c3173cec3a0732f8c09a0a31